Brief: BioXcel Therapeutics Q4 Basic EPS USD -0.76
12/03/2024 11:00
Mar 12 (Reuters) - BioXcel Therapeutics Q4 revenue USD 376 thousand vs. IBES estimate USD 711.1 thousand. * Q4 operating expenses USD 20.251 million * Q4 operating income USD -19.875 million * Q4 net income USD -22.256 million
Recent news on BioXcel Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Bleichroeder Acquisition Corp, Halliburton, BioNTech
U.S. STOCKS ON THE MOVE-Halliburton, BioNTech, Kazia Therapeutics
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna
Brief: Bioxcel Therapeutics Enters Into Asset Sale Agreement With Teva Pharmaceuticals
U.S. STOCKS ON THE MOVE-Cytokinetics, Moderna, Ulta Beauty